Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant Methylation of <b> <i>DPYD</i> </b> Promoter, <b> <i>DPYD</i> </b> Expression, and Cellular Sensitivity to 5-Fluorouracil in Cancer Cells

15 Oct 2004

Abstract excerpt

PURPOSE: Dihydropyrimidine dehydrogenase (DPD), the initial rate-limiting enzyme in the degradation of 5-fluorouracil (5-FU), is known to be a principal factor in clinical responses to the anticancer agent 5-FU, and various reports have clearly demonstrated that DPD activity is closely correlated to mRNA levels. However, the regulatory mechanisms of DPD gene (DPYD) expression remain unclear. In this study, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Colorectal Cancer Treatments and Studies
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15501990
DOI: 10.1158/1078-0432.ccr-04-0337

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant Methylation of <b> <i>DPYD</i> </b> Promoter, <b> <i>DPYD</i> </b> Expression, and Cellular Sensitivity to 5-Fluorouracil in Cancer CellsPMID 15501990Read ↗

Comparative Functional Analysis of <i>DPYD</i> Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase ActivitySemantic proximity Read ↗

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.Semantic proximity Read ↗

Phenotypic Profiling of <i>DPYD</i> Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and <i>In Vitro</i> Measurement of Enzyme ActivitySemantic proximity Read ↗

Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.Semantic proximity Read ↗

Germline <i>cis</i> variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase ( <i>DPYD</i> )Semantic proximity Read ↗

Sequence analysis of the 5'-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues.Semantic proximity Read ↗

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.Semantic proximity Read ↗

[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].Semantic proximity Read ↗

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.Semantic proximity Read ↗

Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.Semantic proximity Read ↗

Long noncoding RNA LINC00261 induces chemosensitization to 5‐fluorouracil by mediating methylation‐dependent repression of DPYD in human esophageal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.